Clinical trials: Gastric Cancer (GC), open to volunteers
ESCC, Gastric Adenocarcinoma
Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
This is a single-arm, multi-center phase II study to evaluate the efficacy and safety of sacituzumab tirumotecan (Sac-TMT/SKB264) combined with tagitanlimab (KL-A167) as 2nd line therapy for recurrent or metastatic esophageal…
- Conditions
- ESCC, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- NCT07701681
- Testing
- Sacituzumab Tirumotecan + Tagitanlimab
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
Gastric Cancer is one of the leading causes of cancer-related death worldwide, and patients with unresectable locally advanced or metastatic disease have a poor prognosis.
- Trial name
- NCT07689851
- Testing
- COPOX, Radiotherapy, SHR-1701
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
Gastrointestinal (GI) cancers remain a major global health burden, largely due to the lack of effective and accessible early screening strategies.
- Conditions
- Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- MiGIC (NCT07224750)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Small Cell Lung Cancer (SCLC), Colorectal Carcinoma (CRC)
THE-0504 in Patients With Solid Tumors
Single-centre, open-label, dose escalation phase I clinical trial, designed to evaluate mainly the safety and tolerability of the antitumor drug THE-0504 in patients with different types of solid tumors.
- Conditions
- Small Cell Lung Cancer (SCLC), Colorectal Carcinoma (CRC), Gastric Cancer (GC), Triple -Negative Breast Cancer
- Trial name
- NCT07646106
- Testing
- THE-0504
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Thena Biotech S.r.l.
Solid Tumours, Sarcoma
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which…
- Conditions
- Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer
- Trial name
- INVOKE (NCT06789172)
- Testing
- OKN4395, Pembrolizumab, Fasting
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Epkin
Gastric Cancer (GC), Double-tract Reconstruction
Comparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer
This study includes patients diagnosed with proximal gastric cancer (Siewert type II/III, cT1-3N0-1M0) across six tertiary hospitals, who underwent either double-tract reconstruction (DTR) or tubular gastric anastomosis (TGA).
- Conditions
- Gastric Cancer (GC), Double-tract Reconstruction, Tubular Gastric Anastomosis
- Trial name
- NCT07635836
- Testing
- Double-tract reconstruction
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Qilu Hospital of Shandong University
Gastric Cancer (GC)
A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer
Eligible patients were randomized into two groups: the sodium propionate group and the control group. In the control group, patients received placebo combined with anti-PD-1 therapy plus chemotherapy without additional sodium…
- Trial name
- PAPGC (NCT07615907)
- Testing
- Sodium propionate
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Jinling Hospital, China
Gastric Cancer (GC), Premalignant Lesion
AI-Based Risk Prediction Model for Upper Digestive Tract Cancer
Upper digestive tract cancers are often preceded by pre-malignant lesions, but there is limited evidence regarding optimal risk prediction models and screening strategies for disease progression and cancer development.
- Conditions
- Gastric Cancer (GC), Premalignant Lesion, Gastric Intestinal Metaplasia, Atrophic Gastritis
- Trial name
- NCT07605312
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Liver Neoplasms, Gastric Cancer (GC)
A Subharmonic-Aided Pressure Estimate Technology for Prediction of Response to Systemic Therapy in Gastric Cancer Liver Metastases
Gastric cancer is a common type of cancer that often spreads to the liver. When cancer spreads to the liver, treatment becomes very difficult. Many patients will undergo chemotherapy to shrink the tumor.
- Conditions
- Liver Neoplasms, Gastric Cancer (GC), Gastric Cancer Metastatic to Liver
- Trial name
- NCT07581730
- Testing
- SHAPE
- Volunteers
- 107 people
- Sponsor
- The First Hospital of Jilin University
Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC)
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
The goal of this interventional clinical study is to learn the safety and preliminary efficacy of XH001 injection (Personalized mRNA tumor neoantigen vaccine) combined with standard adjuvant treatment in treating patients with…
- Conditions
- Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC), Hepatocellular Carcinoma (HCC), Gastric Cancer (GC)
- Trial name
- NCT07594964
- Testing
- XH001 Injection, mFOLFIRINOX Treatment Regimen
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Shenzhen Xinhe Biomedical
Gastric Cancer (GC), Locally Advanced Gastric Cancer
Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
Gastric cancer is a major global health challenge. Currently, a combination of chemotherapy and immunotherapy (PD-1 inhibitors) is frequently used before surgery to shrink tumors, a strategy known as neoadjuvant therapy.
- Trial name
- NCT07401199
- Testing
- Standard of Care PD-1 Inhibitors, Multimodal AI Assessment
- Where
- 9 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Qun Zhao
Gastric Cancer (GC), Pancreatic Cancer
Prediction of Peritoneal Dissemination of Digestive Tumors Through the Study of Circulating Tumor DNA
The peritoneum is a relatively frequent metastatic site in digestive tumors (colon, stomach, pancreas) and is characterized by a poorer prognosis compared with other metastatic sites such as the lung or liver.
- Conditions
- Gastric Cancer (GC), Pancreatic Cancer, Colorectal Cancer
- Trial name
- PREDIPER (NCT07574957)
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Gastric Cancer (GC), Siewert Type III Adenocarcinoma of Esophagogastric Junction
Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer
Proximal gastric and esophagogastric junction cancers comprise up to 40% of gastric malignancies. For localized disease, proximal gastrectomy is the main radical procedure, but reconstruction of GI tract often leads to…
- Conditions
- Gastric Cancer (GC), Siewert Type III Adenocarcinoma of Esophagogastric Junction, Siewert Type II Adenocarcinoma of Esophagogastric Junction
- Trial name
- PROXISTAT (NCT07441785)
- Testing
- Proximal Gastrectomy
- Where
- Russia
- Volunteers
- 400 people
- Sponsor
- P. Herzen Moscow Oncology Research Institute
Gastric Cancer (GC), Gastric Adenocarcinoma
Laparoscopic Staging for Stage III Gastric Cancer
This study aims to determine, through a multicenter randomized controlled design, the impact of precision treatment guided by laparoscopic staging on overall survival (OS), surgical conversion rate, and peritoneal metastasis rate…
- Trial name
- CGCA202501 (NCT07533825)
- Testing
- Laparoscopic Staging-Guided Therapy, Without Laparoscopic Exploration
- Where
- China
- Volunteers
- 968 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric Cancer (GC), AFP Gastric or Gastroesophageal Junction Adenocarcinoma
Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma
Alpha-fetoprotein-producing gastric cancer (AFP-positive gastric cancer, AFP-GC), a rare and highly aggressive subtype of gastric cancer, accounts for 1.3% to 15% of all gastric cancer cases.
- Trial name
- NCT07515625
- Testing
- Sintilimab, Bevacizumab, Oxaliplatin
- Volunteers
- 46 people
- Sponsor
- Fudan University
Gastric Cancer (Diagnosis), Gastric Cancer (GC)
A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma
This study is a domestic, multicenter, single-arm clinical trial designed to evaluate the efficacy and safety of heterogeneous radiotherapy (high and low dose) sequenced with iparomlimab and tuvonralimab plus SOX as a first-line…
- Conditions
- Gastric Cancer (Diagnosis), Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT07502027
- Testing
- Iparomlimab and Tuvonralimab (QL1706)
- Volunteers
- 55 people
- Sponsor
- Huazhong University of Science and Technology
Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC)
QLS5132 Combination Therapy in Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5132 (injectable) in combination with other therapies for participants with advanced…
- Conditions
- Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors
- Trial name
- NCT07453394
- Testing
- QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab
- Volunteers
- 626 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Gastric Cancer (GC), Postoperative Recovery
Early Postoperative Intervention in Gastric Cancer Patients
This study was conducted by Qilu Hospital and five other renowned medical centers, aiming to evaluate the impact of early structured postoperative intervention on quality of life and prognosis in patients with gastric cancer…
- Trial name
- NCT07444099
- Testing
- Early structured postoperative intervention encompassing nutrition, psychology, and exercise
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Qilu Hospital of Shandong University
Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC)
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Evaluate the efficacy and safety of SH009 injection therapy for patients with advanced solid tumors
- Conditions
- Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC), Head and Neck Cancer Squamous Cell Carcinoma, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- NCT07390838
- Testing
- SH009
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Gastric Cancer (GC), Adjuvant Chemotherapy
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
This is a multicenter, open-label, phase 3, randomized, non-inferiority study aimed to investigate the effect on disease-free survival of adjuvant chemotherapy with oxaliplatin plus S-1 compared with adjuvant chemotherapy with…
- Conditions
- Gastric Cancer (GC), Adjuvant Chemotherapy, Stage 3 Cancer, Docetaxel
- Trial name
- NCT07366528
- Testing
- Oxaliplatin plus S-1, Docetaxel plus S-1
- Where
- 5 sites in China
- Volunteers
- 387 people
- Sponsor
- Ruijin Hospital